Promising Target For New Atherosclerosis Therapies Linked To Leukemia

... In recent years, scientists studying inflammation and atherosclerosis have seen their respective fields converging, with research findings showing chronic inflammation as a driver of the atherosclerotic process. Now, in a new study, scientists at the Wistar Institute pursuing a promising new immune-system target for anti-atherosclerosis therapies have discovered another convergence: An unwanted potential side effect of any such therapies is a dangerous blood cancer called chronic myelogenous leukemia, or CML. ...